Thomas John Dietz, Director at Eiger BioPharmaceuticals, Inc. (EIGR), bought 1,000 shares at $4.95 ($5K) on 2020-03-16, disclosed to the SEC on 2020-03-17.
Open-market purchase of $5k EIGR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| EIGR | SELL | 2022-12-27 | $26K | — | Filing → |
| EIGR | BUY | 2021-04-12 | $21K | — | Filing → |
| EIGR | BUY | 2020-01-13 | $56K | — | Filing → |